INT280017

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 2.31
Pain Relevance 0.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (NOLC1) mitosis (NOLC1) nucleolus (NOLC1)
nucleus (NOLC1) cell cycle (NOLC1) DNA binding (NOLC1)
NOLC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 1 97.72 Very High Very High Very High
fibrosis 7 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
agonist 2 5.00 Very Low Very Low Very Low
methadone 2 5.00 Very Low Very Low Very Low
drug abuse 1 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
addiction 1 5.00 Very Low Very Low Very Low
Paracetamol 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatitis C Virus Infection 175 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 18 99.32 Very High Very High Very High
Nicotine Addiction 2 89.80 High High
Infection 111 89.28 High High
Hepatitis 4 50.00 Quite Low
Liver Disease 11 45.88 Quite Low
Disease 4 42.64 Quite Low
Hepatocellular Cancer 6 18.52 Low Low
Cirrhosis 9 5.00 Very Low Very Low Very Low
Fibrosis 7 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Moreover, Iran has one of the highest per capita rates of opioid use in the world.18 Thus, in the Iranian context, incarceration of drug users may be particularly detrimental to controlling the spread of HCV.
Regulation (controlling) of HCV associated with hepatitis c virus infection and opioid
1) Confidence 0.33 Published 2009 Journal J Urban Health Section Body Doc Link PMC2791818 Disease Relevance 1.38 Pain Relevance 0.10
Only two direct-acting HCV inhibitors entered phase III trials in 2008, both of which are PIs (telaprevir and boceprevir).31 The success of HIV antiviral therapy gave hope that HCV NS3-4A protease could be an excellent target for a structural-base design approach.
Regulation (target) of HCV associated with acquired immune deficiency syndrome or hiv infection and hepatitis c virus infection
2) Confidence 0.00 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731021 Disease Relevance 0.92 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox